Setting new standards in information exchange for the pharmaceutical and biotech industry
Rational Combinations 360° & IO360° Lead Advisor, Dr Axel Hoos, GSK Speaks on Prioritizing Immunotherapy Combinations
May 3, 2017
Dr Axel Hoos, SVP, Oncology R&D, GSK, shares his insights on the drivers behind prioritizing combinations in order to have the most transformation effect for cancer patients in a video interview with Dr James Gulley, NCI and Valerie Bowling, Immuno-Oncology 360° (IO360°).
“The breadth of modalities, what we have today, is enormous,” said Dr Axel Hoos, SVP, Oncology R&D, GSK in an earlier interview with Valerie Bowling. “There is a lot of opportunity arising from it. It also brings complexity. The maximum value of different modalities will most likely come from combining them,” said Dr Hoos in an earlier interview with Bowling.
Dr Hoos will be co-chairing and moderating a partnership panel at the 2nd annual Rational Combinations 360°, taking place June 28-29, 2017 at The New York Academy of Medicine, NYC. The program, led by industry and academic leaders, addresses scientific, clinical and business developments in IO combination strategies to fight a wider range of cancers.
Click to Watch Video